Breast cancer surgery: opioid-free anesthesia associated with less short-term inflammation

Two anesthetic strategies compared

The researchers studied women undergoing quadrantectomy, a procedure that removes part of the breast. Random allocation created two groups of 34 patients: one received conventional general anesthesia with opioids, while the other received opioid-free general anesthesia combined with regional blocks.

Blood samples were collected before surgery, then one hour and 24 hours afterward. The primary outcome was the neutrophil-to-lymphocyte ratio, or NLR, an indicator of the inflammatory response. The researchers also collected data on circulating cytokines, pain and adverse effects.

A biological difference, not yet a lasting benefit

At 24 hours, the median change in NLR from baseline was +0.64 in the opioid group, compared with +0.11 in the opioid-free group with blocks. Inflammatory cytokines followed the same pattern, with larger increases in the conventional group.

The abstract reports a statistically significant increase in NLR from baseline in the opioid group, but not in the other group. This difference in statistical significance does not, by itself, constitute a test of the difference between groups. Nevertheless, the abstract concludes that the opioid-free strategy reduced the postoperative inflammatory response.

Pain control was similar in both groups. The opioid-free strategy was also described as better tolerated, with fewer adverse effects. However, the abstract specifies neither their nature nor their frequency, making it impossible to assess the magnitude of this advantage.

What this trial cannot establish

The comparison involves two complete strategies. It does not allow the observed difference to be attributed solely to the removal of opioids, independently of the regional blocks.

The inflammatory measurements presented extend only to 24 hours. They demonstrate neither better long-term recovery nor an improvement in cancer prognosis. The authors themselves state that further research is needed to establish whether these biological effects translate into clinical benefits.

What we can take away

This trial supports the value of studying opioid-free anesthesia combined with regional blocks in breast surgery. It is not sufficient to establish lasting clinical superiority.